Objective: This study assessed the employer cost burden of predialysis CKD-related anemia for a major US manufacturer, by examining indirect and direct costs before and after initiation of epoetin alfa (EPO).
Methods: Hemoglobin (Hb) levels, direct costs, and indirect costs for employees with CKD-related anemia were collected for 15 months (9 months pre-EPO and 6 months concurrent/post-EPO treatment). Indirect costs (absenteeism and presenteeism) and direct costs (medical and pharmacy) were compared for the pre- and post-EPO treatment periods.
Results: Treating CKD-related anemia with EPO increased Hb levels from 9.4 (1 to 3 months pre-EPO)to 12.2 g/dL (4 to 6 months post-EPO), decreased absenteeism by 52.3 days per patient per year (PPPY), increased productivity by 91.5% PPPY, and reduced health care costs by approximately $4417 PPPY.
Conclusion: Among employees with predialysis CKD-related anemia, EPO treatment was associated with increased Hb levels, improved productivity, and decreased direct employer costs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JOM.0b013e318162f615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Roxadustat for CKD-related anemia: a unified solution for non-dialysis, dialysis, and post-transplant patients.
Int Urol Nephrol
January 2025
Rahbar Medical and Dental college, Lahore, Pakistan.
Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease.
Toxins (Basel)
November 2024
Anemia Working Group of the Spanish Society of Nephrology, 39008 Santander, Spain.
Article Synopsis
- Gut dysbiosis in chronic kidney disease (CKD) has been linked to anemia due to factors like increased uremic toxins, inflammation from gut barrier issues, and reduced production of beneficial short-chain fatty acids (SCFAs).
- Addressing gut dysbiosis can help manage anemia in CKD patients by reducing harmful medications, incorporating dietary changes, and using prebiotics or probiotics to enhance beneficial gut bacteria.
- Improving gut health in CKD not only alleviates anemia symptoms but can also boost the effectiveness of treatments like erythropoiesis-stimulating agents (ESAs) in patients unresponsive to standard therapies.
Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder.
Kidney Blood Press Res
October 2024
Department of Medicine, Pederzoli Hospital, Nephrology and Dialysis Unit, University of Verona, Verona, Italy.
Background: Physical exercise (PE) can regulate inflammation, cardiovascular health, sarcopenia, anaemia, and bone health in the chronic kidney disease (CKD) population. Experimental and clinical studies both help us better understand the mechanisms that underlie the beneficial effects of the exercise, especially in renal anaemia and CKD-mineral bone disorders (CKD-MBDs). Here, we summarize this evidence, exploring the biological pathways involved, locally released substances, and crosstalk between tissues, but also the shortcomings of current knowledge.
View Article and Find Full Text PDFQuality of life in people with chronic kidney disease: focusing on modifiable risk factors.
Curr Opin Nephrol Hypertens
November 2024
School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
Purpose Of Review: With ageing populations and rising prevalence of key risk factors, the prevalence of many long-term conditions including chronic kidney disease (CKD) is increasing globally. Health-related quality of life (HRQoL) is important to people living with CKD but not all HRQoL determinants are modifiable. This review summarizes recently identified potentially modifiable factors affecting HRQoL for people with CKD and recent trials incorporating HRQoL as an outcome.
View Article and Find Full Text PDFPhysician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling.
Patient Prefer Adherence
July 2024
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Background: Several treatment options are available for anemia associated with chronic kidney disease (CKD); however, there remains a lack of awareness of physician and patient preferences regarding these treatments. We aimed to explore physicians' and patients' perceptions and preferences regarding the management of anemia of CKD in Japan.
Methods: A web-based survey, including best-worst scaling (BWS), was conducted with physicians who had treated ≥1 patient with anemia of CKD in the preceding year, and with patients with CKD who self-reported a clinical diagnosis of anemia of CKD or low hemoglobin levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!